THURSDAY, OCTOBER 10, 2019
7:15 AM TO 4:30 PM
Biomedical Research Building | Gaulton Auditorium
421 Curie Boulevard | Philadelphia, PA 19104

Penn Medicine’s Abramson Cancer Center and
The Italian Consulate General of Philadelphia PRESENT

ITALY-PHILADELPHIA CONVERGENCE ON KIDNEY CANCER:
FOCUS ON ADVANCING RESEARCH TOWARD PATIENT CARE

A CME-accredited Conference

REGISTER AT PennMedicine.org/Abramson/KidneyCME19
OVERVIEW

The surgical and medical treatment of kidney cancer has changed dramatically in the last several years and continues to evolve. Economic and educational frameworks differ between Europe and the United States, which shape approaches to cancer research differently. Experts from Italy and the United States have been assembled to interact and discuss the latest advances in kidney cancer care and research including the biology of kidney cancer, best practices in patient care, novel approaches to diagnosis and treatment, and the future of therapy.

Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care and understanding new strategies to optimize and improve kidney cancer therapies. Participants will leave with up-to-date, practical information which will have immediate clinical application, as well as technical and scientific background on the current state, and where the latest scientific advances may take the field.

OBJECTIVES

Upon completion of this conference, participants should be able to:

• Identify molecular characteristics, metabolic targets and immunology of kidney cancer
• List concepts regarding how kidney cancer biology informs treatment options
• Implement current standards of care to maximize curative therapy
• Identify key areas for the future of kidney cancer therapy including: combination or monotherapy, immunotherapy, central anti-oncogenic pathways in ccRCC, cellular therapies and emerging novel therapies

WHO SHOULD ATTEND

This activity is designed for physicians, basic and translational researchers, representatives from industry, and other healthcare professionals caring for patients with kidney cancer. Target medical specialties include medical oncologists, urologists, radiologists, and pathologists. Additionally, advocates who may benefit from understanding current innovative approaches to kidney cancer care are invited.

Penn’s Abramson Cancer Center gratefully acknowledges the Mazzoleni Family Research Fund for support of this conference.
AGENDA

7:15 am  Check-in and Breakfast
7:45 am  Welcome
Naomi B. Haas, MD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Cancer Center
Robert H. Vonderheide, MD, DPhil // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Cancer Center
The Honorable Pier Forlano // Consul General of Italy in Philadelphia

SESSION 1:  KIDNEY CANCER BIOLOGY REVEALED
MODERATOR: M. Celeste Simon, PhD
8:15 am  New Models and Treatments for Clear Cell Renal Cell Carcinoma Emerging from Studies of the VHL Tumor Suppressor Gene
William G. Kaelin, Jr., MD // Harvard Medical School // Dana-Farber/Harvard Cancer Center
8:25 am  Targeting Metabolism and Kidney and Liver Cancer
M. Celeste Simon, PhD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Family Cancer Research Institute
8:45 am  Understanding the Microbiome in Cancer
Andrea Facciabene, PhD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Cancer Center
9:05 am  SPECIAL GREETING – Kidney Cancer Biology with respect to Cancer Research
Margaret Foti, PhD, MD (hc) // Chief Executive Officer, American Association for Cancer Research
9:25 am  Immunology of Kidney Cancer
Kerry Campbell, PhD // Lewis Katz School of Medicine at Temple University // Fox Chase Cancer Center
9:45 am  Panel discussion
10:15 am  Break

SESSION 2:  BIOLOGY INFORMS THERAPY OPTIONS
MODERATOR: Katherine L. Nathanson, MD
10:30 am  New Developments in Hereditary Kidney Cancer
Katherine L. Nathanson, MD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Cancer Center
10:50 am  Cilia and Cell Signaling
Erica A. Golemis // Lewis Katz School of Medicine at Temple University // Fox Chase Cancer Center
11:10 am  Epigenetics and Kidney Cancer
Roberto Pili, MD // Indiana University School of Medicine
11:30 am  Drug Development Approaches to Kidney Cancer
TBA
11:50 am  Global Approaches to Clinical Trials in Kidney Cancer
Cora N. Sternberg, MD // Weill Cornell Medicine // Joan & Sanford I. Weill Medical College of Cornell University

12:10 pm  Panel discussion
12:30 pm  LUNCH

SESSION 3:  MAXIMIZING CURATIVE THERAPY
MODERATOR: Naomi B. Haas, MD
1:00 pm  Does Perioperative Therapy Cure More Kidney Cancer?
Robert G. Uzzo, MD // Lewis Katz School of Medicine at Temple University // Fox Chase Cancer Center
1:20 pm  Minimizing Big Surgeries
Gino Gerosa, MD // Padova University Hospital
1:40 pm  Novel Imaging, Therapies and How to Reach Kidney Cancer
Mark A. Rosen, MD, PhD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Cancer Center
2:00 pm  Angiogenic Therapy and Kidney Cancer
Naomi B. Haas, MD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine // Abramson Cancer Center
2:20 pm  Panel discussion
2:40 pm  Break

SESSION 4:  THE FUTURE OF THERAPY
MODERATOR: Naomi B. Haas, MD
2:45 pm  Combination or Monotherapy for Advanced Disease, How do we Choose?
Elizabeth Plimack, MD, MS // Lewis Katz School of Medicine at Temple University // Fox Chase Cancer Center
3:05 pm  Central Anti-Oncogenic Pathways in ccRCC
Haifeng Yang, PhD // Sidney Kimmel Medical College // Jefferson - Philadelphia University and Thomas Jefferson University
3:25 pm  Cellular Therapies for Kidney Cancer
Regina M. Young, PhD // Perelman School of Medicine at the University of Pennsylvania // Penn Medicine
3:45 pm  The Future of Novel Therapies for Kidney Cancer
Camillo Porta, MD // IRCCS Istituti CliniciScientifici Maugeri
4:05 pm  Panel Discussion
4:30 pm  Adjourn

ACREDITATION AND DESIGNATION OF CREDIT
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS: Penn Medicine designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 7.75 Category 1 credits for completing this activity.
Penn Medicine’s Abramson Cancer Center and The Italian Consulate General of Philadelphia PRESENT

ITALY-PHILADELPHIA CONVERGENCE ON KIDNEY CANCER:
FOCUS ON ADVANCING RESEARCH TOWARD PATIENT CARE

A CME-accredited Conference

THURSDAY, OCTOBER 10, 2019
7:15 AM TO 4:30 PM

REGISTER AT PennMedicine.org/Abramson/KidneyCME19